Trial: 202001143

An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy(KEYNOTE667)

Phase

II

Principal Investigator

Hayashi, Robert

Disease Site

Hodgkin Lymphoma

Learn more about this study at: clinicaltrials.gov